Department of Clinical Science, Faculty of Veterinary Medicine, Shahid Bahonar University of Kerman, P.O Box 76169133, Kerman, Iran.
Department of Clinical Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Sci Rep. 2021 Oct 26;11(1):21098. doi: 10.1038/s41598-021-00746-0.
Gene expression profiling has been vastly used to extract the genes that can predict the clinical outcome in patients with diverse cancers, including diffuse large B-cell lymphoma (DLBCL). With the aid of bioinformatics and computational analysis on gene expression data, various prognostic gene signatures for DLBCL have been recently developed. The major drawback of the previous signatures is their inability to correctly predict survival in external data sets. In other words, they are not reproducible in other datasets. Hence, in this study, we sought to determine the gene(s) that can reproducibly and robustly predict survival in patients with DLBCL. Gene expression data were extracted from 7 datasets containing 1636 patients (GSE10846 [n = 420], GSE31312 [n = 470], GSE11318 [n = 203], GSE32918 [n = 172], GSE4475 [n = 123], GSE69051 [n = 157], and GSE34171 [n = 91]). Genes significantly associated with overall survival were detected using the univariate Cox proportional hazards analysis with a P value < 0.001 and a false discovery rate (FDR) < 5%. Thereafter, significant genes common between all the datasets were extracted. Additionally, chromosomal aberrations in the corresponding region of the final common gene(s) were evaluated as copy number alterations using the single nucleotide polymorphism (SNP) data of 570 patients with DLBCL (GSE58718 [n = 242], GSE57277 [n = 148], and GSE34171 [n = 180]). Our results indicated that reticulon family gene 1 (RTN1) was the only gene that met our rigorous pipeline criteria and associated with a favorable clinical outcome in all the datasets (P < 0.001, FDR < 5%). In the multivariate Cox proportional hazards analysis, this gene remained independent of the routine international prognostic index components (i.e., age, stage, lactate dehydrogenase level, Eastern Cooperative Oncology Group [ECOG] performance status, and number of extranodal sites) (P < 0.0001). Furthermore, no significant chromosomal aberration was found in the RTN1 genomic region (14q23.1: Start 59,595,976/End 59,870,966).
基因表达谱分析已被广泛用于提取能够预测不同癌症患者临床结局的基因,包括弥漫性大 B 细胞淋巴瘤 (DLBCL)。借助于基因表达数据的生物信息学和计算分析,最近已经开发出各种用于 DLBCL 的预后基因特征。以前的特征的主要缺点是它们无法在外部数据集正确预测生存。换句话说,它们在其他数据集中不可重复。因此,在这项研究中,我们试图确定能够在 DLBCL 患者中可重复且稳健地预测生存的基因。从包含 1636 名患者的 7 个数据集(GSE10846[n=420]、GSE31312[n=470]、GSE11318[n=203]、GSE32918[n=172]、GSE4475[n=123]、GSE69051[n=157]和 GSE34171[n=91])中提取基因表达数据。使用单变量 Cox 比例风险分析检测与总生存显著相关的基因,P 值<0.001,假发现率 (FDR)<5%。此后,提取所有数据集之间共同的显著基因。此外,使用 570 名 DLBCL 患者的单核苷酸多态性 (SNP) 数据(GSE58718[n=242]、GSE57277[n=148]和 GSE34171[n=180])评估最终共同基因(s)对应区域的染色体异常。我们的结果表明,网蛋白家族基因 1 (RTN1) 是唯一满足我们严格管道标准且与所有数据集的有利临床结局相关的基因(P<0.001,FDR<5%)。在多变量 Cox 比例风险分析中,该基因仍然独立于常规国际预后指数成分(即年龄、分期、乳酸脱氢酶水平、东部合作肿瘤组[ECOG]表现状态和结外部位数量)(P<0.0001)。此外,在 RTN1 基因组区域(14q23.1:起始 59,595,976/结束 59,870,966)未发现明显的染色体异常。